Hsu Yu-Chen, Fu Hsiao-Hui, Jeng Yung-Ming, Lee Po-Huang, Yang Shiaw-Der
Laboratory of Molecular and Cellular Oncology, Institute of Molecular and Cellular Biology, and Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan, ROC.
J Clin Oncol. 2006 Aug 10;24(23):3780-8. doi: 10.1200/JCO.2005.03.7499. Epub 2006 Jun 5.
Molecular, cellular, and animal studies have established that overexpressed proline-directed protein kinase F(A) (PDPK F(A)) is essential for the development of tumorigenesis, invasion, and metastasis of human cancer cells. However, the prognostic role of PDPK F(A) in cancer patients remains largely unknown. In this study, association of PDPK F(A) expression with poor prognosis of hepatocellular carcinoma (HCC) patients was examined.
PDPK F(A) expression in the resected tumors of 134 HCC patients (112 men and 22 women) with ages ranging from 33 to 83 years (mean, 55 years) was analyzed by immunohistochemistry. Highly condensed cytoplasmic and nuclear PDPK F(A) associated with tumor cells was used as the major scoring parameter for positive PDPK F(A) expression.
Approximately 68% of the patients (91 of 134) exhibited positive PDPK F(A) expression. Patients with positive PDPK F(A) showed poorer disease-free survival and overall survival (P < .001). Cox multivariate regression analysis further established PDPK F(A) as the strongest independent prognosticator for progression and patient survival of HCC (hazard ratio [HR], 2.878; 95% CI, 1.634 to 5.067 for disease-free survival; and HR, 5.035; 95% CI, 2.137 to 11.866 for overall survival; P < .001).
Consistent with PDPK F(A)'s essential role in the development of highly malignant phenotypes, the present study establishes the potential prognostic role of PDPK F(A) in progression and patient survival of surgically resected primary HCC. Taken together, PDPK F(A) represents a new modifiable signal-transducing target for prognostic prediction and adjuvant treatment of patients with aggressive HCC after hepatic resection.
分子、细胞及动物研究已证实,过表达的脯氨酸定向蛋白激酶F(A)(PDPK F(A))对人类癌细胞的肿瘤发生、侵袭及转移发展至关重要。然而,PDPK F(A)在癌症患者中的预后作用仍 largely 未知。在本研究中,检测了PDPK F(A)表达与肝细胞癌(HCC)患者预后不良的相关性。
对134例年龄在33至83岁(平均55岁)的HCC患者(112例男性和22例女性)切除肿瘤中的PDPK F(A)表达进行免疫组织化学分析。与肿瘤细胞相关的高度浓缩的细胞质和细胞核PDPK F(A)用作PDPK F(A)阳性表达的主要评分参数。
约68%的患者(134例中的91例)表现出PDPK F(A)阳性表达。PDPK F(A)阳性的患者无病生存期和总生存期较差(P <.001)。Cox多变量回归分析进一步确定PDPK F(A)是HCC进展和患者生存的最强独立预后指标(无病生存期的风险比[HR]为2.878;95%CI为1.634至5.067;总生存期的HR为5.035;95%CI为2.137至11.866;P <.001)。
与PDPK F(A)在高度恶性表型发展中的重要作用一致,本研究确立了PDPK F(A)在手术切除的原发性HCC进展和患者生存中的潜在预后作用。综上所述,PDPK F(A)代表了一种新的可调节信号转导靶点,用于肝切除术后侵袭性HCC患者的预后预测和辅助治疗。